A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.
Yokoyama
S
S
National Cardiovascular Center Research Institute, Osaka, Japan.
Yamamoto
A
A
Kurasawa
T
T
D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology*; D011341:Probucol / Q000494:pharmacology* / Q000627:therapeutic use
D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D010636:Phenols; D002994:Clofibrate; D011341:Probucol; D001629:Bezafibrate